• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    MannKind (MNKD) Adds Furoscix And New Approvals, Is The Growth Potential Fully Priced In?

    Simply Wall St·11/02/2026 08:21:16
    Listen to the news

    Event driven interest in MannKind

    Fresh attention on MannKind (MNKD) follows recent analysis of its Furoscix ReadyFlow acquisition and new product approvals, which argues that expectations for improved future cash flows are not fully reflected in the current share price.

    MannKind’s share price has fallen 37.5% year to date and the 1 year total shareholder return is down 36.13%. However, the recent 7 day share price gain of 8.36% hints that momentum may be stabilising as investors reassess the latest approvals and the Furoscix ReadyFlow deal.

    Compare MannKind’s setup with a curated 33 high quality undervalued stocks that currently screens as overlooked on cash flow potential and balance sheet strength.

    MannKind now carries a broader portfolio and fresh approvals, yet the share price still reflects a year of heavy declines with only a recent uptick. Is this a strong business that is temporarily mispriced, or fairly valued after all?

    Most Popular Narrative: 56% Undervalued

    The most followed storyline around MannKind pegs fair value at $7.97, which sits well above the last close at $3.50. As a result, attention naturally shifts to what might justify that gap.

    The Technosphere platform is now supporting a broader set of programs, including nintedanib DPI for idiopathic pulmonary fibrosis, ralinepag DPI with United Therapeutics and the recently signed ROSE 010 inhaled GLP 1 collaboration for weight management. Each additional partner funded or co developed asset increases the number of shots on goal for future royalty, services and product revenue streams.

    See why 10 investors see MannKind as 56% undervalued.

    Result: Fair Value of $7.97 (UNDERVALUED)

    Still, the MannKind story depends on turning recurring losses into sustained profits, and on Afrezza and Furoscix meeting high expectations without hitting competitive or adoption setbacks.

    Find out about the key risks to this MannKind narrative.

    Next Steps

    Mixed signals around MannKind can be confusing. Move quickly from headlines to hard numbers and weigh the risks against the upside yourself by reviewing the 3 key rewards and 1 important warning sign.

    Looking for more MannKind sized investment ideas?

    If MannKind has your attention, do not stop there. Use the Simply Wall St screener to quickly spot other opportunities before they move without you.